QDEL - FDA: COVID antigen tests can detect Omicron but there may be some false negatives

The FDA says that early data indicates that antigen tests for COVID are able to detect the Omicron variant, but may have reduced sensitivity. Sensitivity is the term used to describe the accuracy of a test in the form of the true positive rate. If a test has lower sensitivity, it means that false negative results may become an issue. "Antigen tests are generally less sensitive and less likely to pick up very early infections compared to molecular tests," the FDA said. Antigen tests are the kind that provide rapid results in 15-20 minutes and are used for at-home tests. The data analysis was done in partnership with the NIH's RADx program. COVID test makers: Quidel (QDEL -3.1%), Fulgent Genetics (FLGT -4.7%), Abbott (ABT -0.7%), Roche (OTCQX:RHHBY +0.7%), Hologic (HOLX -1.9%) OraSure (OSUR -3.0%), Becton, Dickinson (BDX -0.5%), Cue Health (HLTH -7.6%), Lucira Health (LHDX -2.2%), Danaher (DHR -1.2%), PerkinElmer (PKI -1.1%), and Fluidigm (FLDM -2.9%). In a meeting with governors

For further details see:

FDA: COVID antigen tests can detect Omicron, but there may be some false negatives